Company profile: OraSure Technologies
1.1 - Company Overview
Company description
- Provider of oral fluid diagnostic and collection devices, offering rapid infectious disease tests (HIV, Hepatitis C, COVID-19, Ebola, influenza), oral fluid-based substance abuse testing, DNA Genotek DNA/RNA sample collection kits for genomics and microbiome research, and the Novosanis Colli-Pee device for first-void urine detection of urological cancers and sexually transmitted infections.
Products and services
- Rapid Diagnostic Tests: OraSure produces rapid infectious-disease test products for HIV, Hepatitis C, COVID-19, Ebola, and influenza, enabling quick identification of infections
- DNA Genotek Sample Collection: DNA Genotek develops DNA/RNA-specific sample collection kits supporting genomics and microbiome research for collecting DNA and RNA
- Oral Fluid Substance Abuse Testing: OraSure offers oral-fluid-based drug and alcohol testing products that simplify collection and reduce tampering risk while detecting substances in saliva.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to OraSure Technologies
DelSiTech
HQ: Finland
Website
- Description: Provider of biodegradable silica-based controlled-release drug delivery technologies and drug development services, focusing on parenteral and local administration. Offers Silica Matrix platform for small molecules, biopharmaceuticals, and viral vectors; long-acting injectables, ocular drug delivery, and supergeneric/505(b)(2) products such as DST1308 and DST2105.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DelSiTech company profile →
Prosetta Biosciences
HQ: United States
Website
- Description: Provider of the Prosetta Platform, a drug discovery platform applying small molecules that modulate assembly of multi-protein complexes for infectious and degenerative diseases. Offers antiviral compounds targeting energy-dependent capsid assembly, an oncology program identifying anti-proliferative agents across ~75 cancers, antibacterial and neurodegenerative research, and PAV-431, a host-targeted antiviral effective against multiple respiratory viruses.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Prosetta Biosciences company profile →
Atriva Therapeutics
HQ: Germany
Website
- Description: Provider of host-targeting antiviral therapies for respiratory viral infections. Its lead candidate, zapnometinib (ATR-002), is an orally available small molecule designed to inhibit viral replication and modulate immune response to treat severe RNA-virus infections. Completed a Phase I safety study; assessing efficacy and safety in a Phase II study in hospitalized severe COVID-19 and planning Phase II development for severe influenza.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Atriva Therapeutics company profile →
SOM Biotech
HQ: Spain
Website
- Description: Provider of AI-based drug discovery and drug repurposing for orphan CNS diseases via the SOM AI PRO platform, validated by two successful Phase 2 trials (TTR amyloidosis; chorea in Huntington’s). Pipeline includes SOM3355 (oral VMAT2 inhibitor, Phase 2b), SOM0226 (TTR stabilizer, outlicensed), SOM1311 (PKU chaperone, expected to enter Phase 2a in 2024), and SOM0034 (DMD program, Phase 2 expected 2025).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SOM Biotech company profile →
Inhibikase Therapeutics
HQ: United States
Website
- Description: Provider of cellular Abelson tyrosine kinase inhibitor therapeutics and platforms for infections and other diseases. Includes Risvodetinib (IkT-148009), an oral drug aimed at halting and reversing Parkinson’s progression in brain and GI; IkT-001Pro, a prodrug of imatinib mesylate for blood and stomach cancers with fewer on-dosing side effects; IkT-01427 to prevent PML; and the RAMP Drug Innovation Engine and Prodrug Delivery Technology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Inhibikase Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for OraSure Technologies
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to OraSure Technologies
2.2 - Growth funds investing in similar companies to OraSure Technologies
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for OraSure Technologies
4.2 - Public trading comparable groups for OraSure Technologies
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →